---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-026871"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:53:32.829033+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aldeyra plans reproxalap NDA resubmission for dry eye disease in H2 2024

## Summary
- Dry eye chamber trial to start H1 2024; NDA resubmission expected H2 2024 if positive.
- FDA review period expected to be six months for potential resubmission.
- Cash $142.8M as of Dec 31, 2023; projected to fund operations beyond 2026.
- Primary endpoint: ocular discomfort; trial design from four prior reproxalap chamber trials.

## SEC filing metadata
- accession: 0001213900-24-026871
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024026871/0001213900-24-026871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024026871/ea0202743-8k_aldey.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-026871
- JSON: https://secwatch.observer/filing/0001213900-24-026871.json
- Plain text: https://secwatch.observer/filing/0001213900-24-026871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.